On the first Biotech Hangout episode of 2023, Daphne, Josh, and Tim are joined by Jefferies’ biotech analyst Michael Yee to recap the deals, financings, and clinical readouts that stood out in 2022. The group discusses the upcoming annual J.P. Morgan Healthcare conference and makes future predictions for 2023, including a possible rebound in China and amore obesity, CNS and small molecule deals. They discuss the Inflation Reduction Act and dive into Jefferies’ January XBI heat map. The group recaps Brad Loncar’s 2023 predictions in Business Insider and discuss what investors will want to see more of this year. They also make predictions for large cap data deals in the next year and share opinions on the recent FDA approval of Eisai’s Alzheimer’s drug, Leqembi. Wrapping up, the group gives final thoughts on M&A deals we can expect to see more of, including deals in oncology and ADC technology.
Community of experts and insiders joining Biotech Hangout (formerly known as Biotech Clubhouse) include Daphne Zohar, Josh Schimmer, Bruce Booth, Tim Opler, Chris Garabedian, Michal Preminger, Dawn Bell, Rob Perez, Otello Stampacchia and more.